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Patients with inflammatory bowel disease have an increasing risk for colorectal cancer  which is believed to begin 
from no dysplasia progressing to indefinite dysplasia, low-grade dysplasia, high-grade dysplasia and finally to 
invasive adenocarcinoma, although colorectal cancer can arise without proceeding through each of these steps. As 
regards to the risk factors predisposing to colorectal cancer in the setting of inflammatory bowel disease, it seems that 
the risk increases with longer duration and greater anatomic extent of colitis, the degree of inflammation, and the 
presence of primary sclerosing cholangitis and family history of colorectal cancer. Concerning the mechanisms of 
carcinogenesis, it is now well established that the molecular alterations responsible for sporadic colorectal 
cancer,namely chromosomal instability, microsatellite instability and hypermethylation, also play a role in colitis-
associated colon carcinogenesis. Chemoprevention strategies include the management of medicaments such as 





 Inflammatory bowel disease (IBD) carries an increased risk of developing colorectal 
cancer (CRC) and depending on study design, length of follow-up, case definitions, environmental 
diversity, treatment strategies the study and country, the risk of developing CRC in patients with 
UC fluctuates between 0.9 to 8.8-fold and between 0.8 and 23-fold in patients with pancolitis.  
IBD-related CRC is estimated to be responsible for less than 2% of all CRC appearing annually 
[1].  
 Eaden et al. accumulate  the results of 116 studies including 55,000 patients with UC [2]. 
In this cohort of patients, 1,700 CRC were diagnosed and the probability of developing CRC 10 
years after diagnosis was 2% , reaching the level of 8% after 20 years and 18% after 30 years. In 
general, the risk of CRC begins to increase 8 or 10 years after the establishment of diagnosis [1]. 
According to a study in Denmark, Winther et al[3] followed 1160 patients with UC over 22 290 
person-years (1962-1987) and found 13 cases of IBD-CRC, giving an annual crude incidence of 
0.06% and cumulative risk of 2.1% at 30 years.  
 They found no statistically significant increase for CRC between IBD and non-IBD 
populations, but it is related with high  colectomy rate. According to a recent analysis the risk of 
CRC has decreased in patients with UC, despite the low frequency of colectomies. The  annual 
incidence rate of CRC in UC ranges from approximately 0.06% to 0.16% with a relative risk of 
1.0-2.75. due to the widespread use of maintenance therapy with 5-ASA compounds and 
surveillance colonoscopy [4].  
 In another population-based study, it was found that the risk for CRC among patients with 
IBD was  associated with the anatomic location of the diseased bowel and  that the risk of rectal 
cancer was increased 2-fold in UC but not in Crohn’s colitis [5].  
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 Patients who have only had small intestinal CD without colonic involvement are not 
considered to be at high risk for CRC. The risk of developing adenocarcinoma in the small 
intestine of patients with small bowel CD is increased, being approximately 10-12-fold greater 
than for the general population[5]. However,  patients with longstanding Crohn’s colitis have 
similar  risk of developing CRC  with UC patients and was shown to be 2.9% at 10 years of 
disease duration, 5.6% at 20 years and 8.3% at 30 years [6]. 
 The risk of colorectal dysplasia and neoplasia in these patients is influenced by 
environmental, genetic and individual factors. It increases with age and this hazard is further 
compounded by specific disease characteristics including disease duration, area of colonic 
involvement, and degree of inflammation.  
 The role of inflammation as a risk factor is supported by the fact that CRC risk increases 
with longer duration of colitis, greater extent of colitis, the concomitant presence of other 
inflammatory manifestations such as primary sclerosing cholangitis, and the fact that certain drugs 
used to treat inflammation may prevent the development of CRC [7].  
 It has been recently shown that cytokines (Interleukin-6 and -23) and growth factors 
released during inflammation may influence the carcinogenesis process [8].  
 Inflammatory cytokines  stimulate a signaling cascade that results in the activation of IKK 
(inhibitor of NF-ĸB kinase), which then phosphorylates IĸB and than it is ubiquitinated and 
degraded, thereby liberating NF-ĸB. Free NF-ĸB translocates to the nucleus where it then induces 
the transcription of target genes. NF-ĸB activation upregulates the expression of many 
proinflammatory mediators including adhesion molecules and cytokines (e.g., TNF-a and IL-6) 
that play a critical role in IBD and have been implicated in tumor development and progression in 
both humans and animal models [9].  
 NF-ĸB has been proposed to be a main molecular link between inflammation and 
carcinogenesis. Moreover, NF-ĸB activation by proinflammatory stimuli can, in turn, directly 
promote cell survival by inducing the production of proteins such as Bcl-2 and Bcl-XL that inhibit 
apoptosis. It also can induce the production of factors that have been shown to drive tumor 
invasion and metastasis including chemokines, matrix metalloproteinases, and serine proteases. 
 Persistent activation of the nuclear factor-ĸB and cyclooxygenase-2/prostaglandin 
pathways, release of proinflammatory mediators such as tumor necrosis factor-a and interleukin-6, 
and enhanced local levels of reactive oxygen and nitrogen species, which induce carcinogenesis in 
the following ways:  
 1) enhancing levels of reactive oxygen and nitrogen species that have mutagenic affects on 
DNA, thus contributing to tumor initiation;  
 2) activating prosurvival and antiapoptotic pathways in epithelial cells, thereby 
contributing to tumor promotion; and  
 3) creating an environment that supports sustained growth, angiogenesis, migration, and 
invasion of tumor cells, thus supporting tumor progression and metastasis [8].  
 According to recent study Toll-like receptor4 (TLR4) signalling is essential  for colon 
carcinogenesis in chronic colitis and its activation appears to promote the development of colitis-
CRC by enhancement of Cox-2 expression and increased EGFR signalling [3]. TNF-a is known to 
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upregulate the production of cyclooxygenase-2 (COX-2) which influence on tumor cell growth 
and angiogenesis.  
 Moreover, inhibition of TNF-a reduced enterocyte levels of nuclear b-catenin, that have 
been implicated in tumorigenesis [9]. iNOS expression is increased during inflammation and 
catalyzes the production of nitric oxide (NO). NO, and reactive species derived from NO  such as 
peroxynitrite, can induce DNA damage and posttranslational modification of DNA repair 
enzymes, apoptotic effectors, and the p53 protein [9].  
 Moreover, the presence of p53 mutations was associated with increased inducible nitric 
oxide synthase (iNOS) activity in these tissues. The tumor suppressor protein p53 plays a key role 
in preventing clonal expansion of mutated cells by initiating apoptosis or cell cycle arrest in cells 
with DNA damage and its alterations  is suggested to be an important early event in colitis-
associated tumorigenesis. Indeed, alterations to the p53 gene occur in 47%– 85% of colitis-
associated cancers.  
 Recent study shows that other factors may contribute to CRC development which  include 
family history of CRC, smoking,  the presence of pseudopolyps and  primary sclerosing 
cholangitis. 
 A family history of CRC increases the risk of CRC by at least two-fold as compared to 
patients with UC without positive family history for CRC [10]. 
 Primary sclerosing cholangitis (PSC) appearing on the ground of UC increases the risk of 
CRC by 4.8-fold compared with patients with UC without PSC and should be enrolled in 
colonoscopic surveillance program regardless of UC duration [11]. 
 There are contradictory results about the younger age at UC onset as a risk factor, a meta-
analysis suggested that the overall annual incidence rate of 0.6% to pediatric patients was only 
numerically higher than that calculated for adults (0.3% ) [2] while other authors suggest that 
younger age at UC onset is an independent risk factor [2]. 
 Smoking reduces the risk of CRC in UC by 50% but increases the risk of CRC in CD 4-
fold, due to the opposite effect smoking has on inflammation in each disease [9]. 
 Pseudopolyps increase the risk of CRC in UC by 2.5-fold as a marker of  severe 
inflammation , or because they may obscure the sensitivity of surveillance colonoscopy [12]. 
 Sporadic CRC originate from mucosal polyps but  colitis-associated CRC may present as flat or 
raised lesions.  Chromosomal instability is the reason for most p53 and APC dysfunction. In sporadic CRC 
an early event in the adenoma-carcinoma pathway is APC dysfunction, whereas p53 mutations are at later 
stages of disease.  
 In colitis-associated CRC, p53 chromosomal abnormalities are observed in earlier stages while  
APC defects are less frequent and seen later in disease course [9,13].  
 This may explain  the flat morphology of dysplasia observed in IBD-associated CRC, as APC 
mutations are considered the reason for polyp formation.  
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Dysplasia 
 Dysplasia is determined as neoplasia of the epithelium localized  to the basement membrane, 
without invasion into the lamina propria and can be classified as raised or flat based on its endoscopic 
appearance [14].  
 Elevated lesions that are endoscopically visible, but not amenable to endoscopic resection are often 
referred to as DALMs (dysplasia associated lesion or mass) referred to the high rate of malignancy 
associated with these lesions [14].   
 ALM (adenoma-like lesion or mass) describe the finding of a polypoid lesion resembling a sporadic 
adenoma that is found in an area of the colon not involved by chronic colitis. Despite the endoscopic 
appearance of a lesion as raised or flat, pathologists use a standardized classification system introduced by 
Riddell and colleagues in 1983 divides dysplasia into categories, including indefinite dysplasia, low grade 
dysplasia (LGD), high grade dysplasia (HGD) and cancer [14].  
 Low-grade tubuloglandular adenocarcinomas usually arise directly from low-grade or even 
indefinite dysplasia. They may progress in turn to more aggressive types of cancer, thus bypassing high-
grade dysplasia. According to a study at the Mount Sinai Hospital, who study the prognosis of patients with 
biopsy description as negative for dysplasia, IND, and flat LGD, showed a 5-year progression rates to HGD 
or CRC of 1.1%, 9% and 45%, respectively [15].  
 Recently Ullman at al, study 56 patients with biopsies reported  indefinite for dysplasia and showed 
a 9.0% 5-year progression rate to HGD or CRC [16]. Regarding the CCFA consensus guideline the patients 
with biopsies indefinite for dysplasia should be followed with annual surveillance examinations. Patients 
with no evidence of dysplasia are consider low-risk for CRC, and should have repeat surveillance 
endoscopy within 1 to 3 years. More recent studies have shown that patients with low-grade dysplasia have 
a lower risk of colorectal cancer than previously were thought (2–10% during a 10-year follow-up) [16], so 
is recommend close colonoscopic surveillance of these patients rather than total colectomy.  
 Five and 10-year progression rates of LGD to HGD and colorectal cancer. Other experts suggest 
that the presence of multifocal low-grade dysplasia should be managed with a total colectomy but when a 
single focus of low-grade dysplasia is found than it should be discussed with the patient. If he refuse 
surgery, then is recommended a second colonoscopy  within 3 months and no later than 6 months from the 
reported  of the low-grade dysplasia [16]. 
 DALMs are associated with increased incidence of CRC and colectomy is generally 
recommended following diagnosis [17]. Several studies have observed a low risk of developing 
CRC after complete endoscopic resection of an adenoma-like DALM (mean follow-up period of 
forty-nine to eighty-two months), when the biopsies from around the lesion and elsewhere in the 
colon show no flat dysplasia [17].  
 An incomplete resection is associated with a significant risk of developing CRC, then 
colectomy is recommended. In practice, once the diagnosis of high grade dysplasia is confirmed 
by a second expert GI pathologist, colectomy is indicated. 
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Conclusion 
 Inflammatory bowel disease clearly predisposes to CRC development although the risk 
differs in different parts of the world. Cancer follows the sequence of no dysplasia, indefinite 
dysplasia, low-grade dysplasia, high-grade dysplasia and carcinoma.  
 Low-grade dysplasia can progress to CRC without the intermediate stage of high-grade 
dysplasia. Similar to sporadic CRC, colitis-associated CRC is a consequence of sequential 
episodes of somatic genetic mutation and clonal expansion. In IBD, neoplastic lesions arise within 
areas of the mucosa that have been involved with colonic inflammation. A balance between cell 
proliferation and apoptosis may partly explain this epidemiological feature.  
 Knowledge of the mechanisms of carcinogenesis could identify patients at high risk for 
development of CRC. In the near future, some chemopreventive agents could play a role in 
reducing the incidence of CRC in IBD patients. The future looks promising with respect to new 
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